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The anti-proliferative effect of Bcl-2 acts mainly at the level of the G0/G1 phase of the cell cycle. Deletions and point mutations in the bcl-
2 gene show that the anti-proliferative activity of Bcl-2, can in some cases, be dissociated from its anti-apoptotic function. This indicates that
the effect of Bcl-2 on cell cycle progression can be a direct effect and not only a consequence of its anti-apoptotic activity. Bcl-2 appears to
mediate its anti-proliferative effect by acting on both signal transduction pathways (NFAT, ERK) and on specific cell cycle regulators (p27,
p130).
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The cell content of an organ is determined by the rate
at which cells proliferate, differentiate and die. These
processes must be coordinated with respect to each other
to assure proper development and functioning of an
organism. However, it is still unclear how cell surface
receptor signals are integrated to co-regulate cellular
events such as proliferation and differentiation or cell
death. Cell proliferation results from the controlled acti-
vation or inactivation of cell-cycle regulators such as
cyclins, protein kinases and phosphatases present in lim-
ited amounts and at specific time points. The control of
this process also includes checkpoints that insure that cells
pass to the next phase of the cell-cycle only when the
previous phase has been completed without default. Fail-
ure to accomplish any step of the cell-cycle will lead to
cell-cycle arrest and/or apoptosis. The cell-cycle and cell
death are thus two intimately linked processes. The reality
of the interconnection of these processes is illustrated by0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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E-mail address: marvel@cervi-lyon.inserm.fr (J. Marvel).the protooncogene c-myc which not only stimulates cell
proliferation but also inhibits cell differentiation and can
induce cells to undergo apoptosis when growth factors are
present in limiting amounts [1–3]. Another example is the
inhibitor of apoptosis (IAP) protein family present in
mammals, insects, nematodes and yeast [4]. Genetical
analysis in Drosophila has clearly established that insect
IAPs function as cell death inhibitors, whereas yeast IAPs
have been shown to play a critical role in meiotic and
mitotic cell division [5]. Furthermore, their closest mam-
malian relative, survivin, appears to be involved in both
regulation of apoptosis and cell division [6,7].
Although Bcl-2 protein and its homologues are key
players in the control of apoptosis, their overexpression in
cell lines or in transgenic animal reveal that they can also
be involved in the control of cell proliferation. Further-
more, the recent report that under-phosphorylated retino-
blastoma protein (Rb) can inhibit the inactivation of Bcl-
xl by deamidation [8] or that CDKs can induce cell death
[9,10] suggests a feedback loop from the cell-cycle to the
apoptosis control machinery allowing cells to integrate the
regulation of these two processes. Functional analysis of
Bcl-2 mutants indicates that the cell-cycle control function
of Bcl-2 family members can in some cases be dissociated
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that high levels of Bcl-2 are associated with a lower
proliferative capacity of human lymphoma suggests that
the effect of Bcl-2 on cell division is physiologically
relevant [11,12]. However, because of their major role
in the control of apoptosis, the impact of the cell-cycle
control function of Bcl-2 family members on the cell
physiology and development of organisms is still not well
defined.2. Effect of Bcl-2 proteins on cell proliferation
2.1. Overexpression of Bcl-2 affects cell-cycle entry
The earliest suspicion of a connection between Bcl-2 and
cell-cycle control was the quiescence of cells overexpressing
Bcl-2 that survived growth factor-starvation-induced cell
death [13]. It was subsequently demonstrated that in the
absence of IL-3, overexpression of Bcl-2 in murine bone
marrow-derived BAF3 cells not only delayed the onset of
apoptosis, but also induced a rapid arrest in the G1 phase of
the cell-cycle. These cells re-enter the cell-cycle in response
to IL-3 with delayed kinetics [14]. The hypothesis of a link
between Bcl-2 and cell-cycle regulation was later reinforced
by the observation that thymocyte turnover is slower in bcl-2-
transgenic mice than in their littermate controls and that B and
T cells expressing the bcl-2 transgene enter the cell-cycle
more slowly than control lymphocytes when stimulated with
mitogens in vitro [15–18]. This extended to primary cells the
observationsmade using established cell lines. Of note, is that
in contrast to Bcl-2 overexpressing T cells, Bcl-2-deficient T
cells showed increased cell-cycle progression [15]. Thus, the
level of Bcl-2 in primary T cells seems to control the duration
of the G0 to S phase transition, with a critical point at the mid
G1 phase (see below) (Fig. 1).Fig. 1. Interactions between Bcl-2 and the cell-cycle. Bcl-2 can affect the progressi
G1 phase. Bcl-2 overexpression has been associated with accelerated G1 arrest or d
cell-cycle has in some cases been associated with control of the exit from G2/M.The anti-proliferative effect of Bcl-2 is shared with
other anti-apoptotic members of the Bcl-2 family such as
Bcl-xl [17,19,20], Bcl-w [20], Mcl-1 [21], as well as with
the adenovirus homologue E1B 19kD [17] and the
Epstein–Barr virus protein BHRF-1 [22].
Interestingly, unlike other anti-apoptotic members of
the Bcl-2 family, overexpression of the Bcl-2 homologue
Bfl-1 facilitates proliferation and oncogene cooperation
[23,24]. In agreement with this observation, overexpres-
sion of A1, the murine homologue of Bfl-1, does not
affect cell-cycle entry when overexpressed in primary T
cells [25].
Finally, it has been demonstrated using bax-transgenic
mice, that overexpression of Bax in the T cell lineage results
in an increased number of cycling thymocytes and that
mature T cells enter S phase in response to IL-2 stimulation
faster than control cells. This effect was associated with an
accelerated decline in the level of the cyclin-dependent kinase
(CDK) inhibitor p27kip1 (p27) [26]. These observations
demonstrate that, although the function of Bcl-2 family
members on cell death and cell-cycle can be dissociated,
overexpression of pro (Bax) and anti-apoptotic (Bcl-2 or Bcl-
xl) members of the Bcl-2 family affects cell-cycle in an
inverse fashion. Moreover, it has been demonstrated that, in
cell lines, Bax can counteract the anti-proliferative effect of
Bcl-2 [17,27]. Similarly, the constitutive expression of Bad in
Bcl-xl overexpressing Rat 1 fibroblasts delayed the G0/G1
arrest induced in culture in low serum conditions [28].
In all the experiments discussed above, Bcl-2 or its
functional homologues retard the cell-cycle progression of
quiescent cells but do not affect the growth of cells that are
continuously cycling in optimal culture conditions or the
proliferation of primary cells after the first division. How-
ever, it has also been reported by Borner [27] that over-
expression of Bcl-2 leads to an increase in the doubling time
of exponentially growing cells.on of cells through two phases of the cell-cycle: the G2/M phase and the G0/
elayed G1/S transition. Phosphorylation of Bcl-2 during the G2 phase of the
Circles represent CDKs and squares cyclins.
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Bcl-2 protein can be post-transcriptionally modified by
phosphorylation at multiple sites (see below), but the
functional consequences of such phosphorylations remain
unclear. Some experiments suggest however, that Bcl-2
phosphorylation is linked to and may affect cell cycle
progression. For example, it has been demonstrated in
okadaic acid-treated HL60 cells that Bcl-2 protein is phos-
phorylated within its unstructured loop, at threonine 56, by
the kinase CDK1 [29]. Phosphorylation at threonine 56
correlated with the accumulation of cells in the G2/M phase
of the cell-cycle and a delayed transition from M to G0/G1
phase upon cell-cycle arrest–release (Fig. 1). Threonine 56
phosphorylation could also be detected in asynchronously
growing cells in the G2 phase of the cell-cycle in the
absence of drug treatment. Interestingly, mutation of threo-
nine 56 to alanine (Bcl-2 T56A) abrogates the cell-cycle
inhibitory effect of Bcl-2 without affecting its anti-apoptotic
effect [29].
Bcl-2, as well as Bcl-xl, are also strongly phosphorylated
in G2/M arrested cells treated with taxoids and other
microtubule-damaging agents, such as paclitaxel (TaxolR)
[30,31]. In this case, phosphorylation also occurs in the
unstructured loop of Bcl-2, as deletion of this loop abrogates
paclitaxel-induced phosphorylation of Bcl-2 [32,33]. Three
residues, serine 70, serine 87 and threonine 69 are phos-
phorylated following paclitaxel-treatment [31,33]. Phos-
phorylation of Bcl-2 on these residues is also observed in
the G2/M phase of asynchronously growing cells [29,31],
serine 70 being the principal phosphorylation site [31].
Results from Yamamoto et al. [31] indicate that the
ASK1/JNK pathway is responsible for both the normal
cell-cycle related and the paclitaxel-induced phosphoryla-
tion of Bcl-2 in the G2/M phase. More recently, phosphor-
ylation of Bcl-2 at serine 70 induced by photodynamic
therapy with the photosensitizer hyperricin [34] has been
reported. Bcl-2 phosphorylation correlates with G2/M arrest
of hyperricin-photosensitized cells preceding apoptosis. In
this case, Bcl-2 phosphorylation is selectively suppressed by
the CDK-inhibitor roscovitine and enhanced by overexpres-
sion of CDK1. However, in vitro active CDK1/cyclin B1
complex failed to phosphorylate Bcl-2, indicating that Bcl-2
might not be a direct substrate of CDK1 as suggested by
other studies [29,35]. The effect of serine 70 phosphoryla-
tion on the anti-apoptotic function of bcl-2 is less clear. In
some systems, it is associated with the down-regulation of
the anti-apoptotic activity of Bcl-2 (Fig. 1) since mutation of
serine 70 to alanine improves this function [31,33,34], while
in other systems the same mutation leads to a decrease in the
anti-apoptotic activity of Bcl-2 [34,36]. These results high-
light the difficulty associated with linking the phosphoryla-
tion of a single Bcl-2 residue with a given functional
modification.
Phosphorylation of Bcl-2 at serine 70 has also been
documented in the presence of other chemotherapeutic
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cin [37] as well as in the presence of growth factors such as
IL-3 or erythropoietin [38]. However, in this case phosphor-
ylation occurs following the activation of PKC and leads to
increased anti-apoptotic function of Bcl-2 [37,39]. Several
other protein kinases including Raf-1 [40], cAMP-depen-
dent protein kinase A [41] and ERK1/2 [42] have been
implicated in the phosphorylation of Bcl-2. However, the
functional significance of Bcl-2 phosphorylation remains
unclear and could be context-dependent.3. Structural domains involved in the cell-cycle
regulatory function of Bcl-2
Structural analysis of the Bcl-xl protein has clarified the
relationship between the anti-apoptotic function and the
domain structure of Bcl-2 family members [43]. The Bcl-2
protein possesses four conserved motifs known as Bcl-2
homology domains (BH1 to BH4) (Fig. 2). The BH1 and
BH2 domains are involved in the homodimerization of Bcl-
2 family members, whereas the BH3 domain is essential for
the pro-apoptotic activity. The BH4 domain is considered to
be essential for anti-apoptotic function, since Bcl-2 mutants
lacking BH4 or with mutated BH4 domain are unable to
block cell death [20,27,44,45].
Some deletion or mutations that affect the anti-apoptotic
activity of Bcl-2 have also been reported to abolish its cell-
cycle inhibitory activity. Indeed, point mutations within
BH1 or BH2 domains at residues 145 (G145E) and 188
(W188A) (Fig. 2), disrupt the cell survival function of Bcl-2
and its ability to interact with Bax [46] as well as its
inhibitory effect on the cell-cycle [17]. Similarly, a Bcl-2
protein deleted of its 36 N-terminal residues loses both anti-
apoptotic and anti-proliferative activities, although its ability
to interact with Bax is conserved (Fig. 2) [17].
However, some modifications can affect cell-cycle inhi-
bition without affecting the inhibition of apoptosis. Those
modifications affect residues comprised in the BH4 domain
or in the unstructured loop located between the BH4 and
BH3 domains. This region is rich in serine and threonine
residues, and is poorly conserved among the different
members of the Bcl-2 family (Fig. 2). The anti-apoptotic
function of Bcl-2 or Bcl-xl was shown to be improved by
deletion of the entire loop region (Bcl-xl D26–83 and Bcl-2
D32–80), indicating that this segment may serve as a
negative regulatory domain of anti-apoptotic function [47].
Interestingly, it was also reported that deletion of a large part
of this loop (residues 51–85) in the bcl-2 gene gives rise to
a protein that retains its anti-apoptotic function but also
facilitates continued cell proliferation [48]. In addition to
these studies, mutational analysis showed that a tyrosine
residue at the amino terminus of the BH4 domain of Bcl-2
and the Bcl-xl and Bcl-w proteins is critical for their effect
on cell-cycle (Figs. 2 and 3). Indeed, Huang et al. [20]
reported that mutation of tyrosine residue 28 of Bcl-2 to
Fig. 2. Mutations and deletions that affect Bcl-2 functions. Conserved BH1 to BH4 domains, transmembrane region (TM) and a-helices are shown below the
sequence. Asterisks indicate phosphorylation sites or critical residues. The unstructured loop is indicated in italics.
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its ability to restrain re-entry, of quiescent FDC-P1 myeloid
cells or NIH 3T3 fibroblasts, into the cell-cycle upon
exposure to growth factors (Fig. 1). This tyrosine residue
is conserved between Bcl-2, Bcl-xl and Bcl-w (Fig. 3) and
similar observations have been reported when these tyrosine
residues (Bcl-xl Y22F or Bcl-w Y27F) are mutated in Bcl-xl
or Bcl-w. This type of mutation does not affect either the
anti-apoptotic activity of Bcl-2 toward p53-mediated cell
death, or its association with the pro-apoptotic molecules
Bax, Bak, Bad or Bid [20]. Thus, these experiments provide
evidence that the anti-apoptotic function of Bcl-2 can be
dissociated from its inhibitory influence on the cell-cycle.
Although bcl-2 was discovered as a candidate oncogene,
conventional transformation assays indicate that it does not
possess dominant oncogenic activity [49]. It is therefore
believed that bcl-2 contributes to oncogenesis primarily byFig. 3. Comparison of the amino acid sequence of the BH4 region of different
program. Identical (dark shading) and similar (light shading) amino acids are marke
2, Bcl-xl (Y22) and Bcl-w (Y27). GenBank accession numbers: nematode Ced-9,
Q92843; human Bcl-B, NP065129; human Mcl-1, Q07820; human Bfl-1, Q1654
human Bcl-rambo, AAK27358.extending cell viability and thereby providing an opportu-
nity for other genetic changes to occur. The anti-prolifer-
ative effect of Bcl-2 may contribute to its poor oncogenic
potential. However, the results discussed above suggest that
a single point mutation on Bcl-2 protein can affect its anti-
proliferative property and thus could increase the oncogenic
activity of Bcl-2 and contribute to tumor progression.
Reinforcing this hypothesis, somatic mutations of the trans-
located bcl-2 gene have been described in follicular lym-
phoma showing a morphologic transformation to diffuse
large-cell lymphoma [50,51,52]. Interestingly, in three out
of four cases, the mutations observed concerned amino
acids 29, 46 and 59, comprised in the unstructured loop
between the BH4 and BH3 domains. The fourth mutation is
located on residue 106 in the BH3 domain. Mutation at
residue 59 would modify the consensus CDK1 phosphor-
ylation site [29].Bcl-2 family members using the Genestream II MSA multiple alignment
d. Sequence alignment indicate the conserved tyrosine residue (Y28) in Bcl-
P41958; human Bcl-2, P10415; human Bcl-XL, NP612815; human Bcl-W,
8; human Bax, Q07812; human Bok, AAF09129.1; human Bak, Q16611;
Fig. 4. Amino acid sequence alignment of Bcl-2 and Bfl-1. Conserved BH1 to BH4 domains and transmembrane region (TM) are indicated. Amino acid
sequences were aligned using the ClustalW alignment program.
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teins of the Bcl-2 family, does not restrain cell prolifera-
tion, but its overexpression permits a rather limited cell
proliferation [23] and cooperates with the E1a oncogene in
transformation of primary rat kidney epithelial cells
[23,24]. Bfl-1 is one of the smallest members of the Bcl-
2 family (175 aa). It shares the four BH1, BH2, BH3 and
BH4 domains with other Bcl-2 family proteins (Fig. 4). A
characteristic of Bfl-1, shared with its murine homologue
A1, is the presence of a Gln-rich N-terminal region that
overlaps with the BH4 domain (Fig. 4). Although muta-
tions within BH1, BH2 or BH4 affect both anti-apoptotic
and proliferation-facilitating activities, mutation of Gln (Q)
residues [18,22] located in the BH4 domain appear to
confer an extended survival in the absence of proliferation
[23]. Moreover, alignment of the Bfl-1 with Bcl-2 primary
structure permits two interesting observations. First, a large
part of the amino acids which constitute the unstructured
loop between BH3 and BH4 domains are not present, and
second, the conserved tyrosine residue (tyrosine 28) is
replaced by a serine. These two characteristics of the Bfl-1
protein mimic deletions or mutations which, when they are
introduced in the Bcl-2 protein, prevent its inhibitory effect
on proliferation.4. Modification of the expression pattern of cell-cycle
regulators is associated with Bcl-2 overexpression in
quiescent cells
Quiescent cells synchronized by deprivation of external
growth stimuli are arrested in the G0 phase of the cell-cycle.
Following mitogenic stimulation, they enter the cell-cycle in
early G1, but this transition is reversible as cells in early G1
can exit into G0 if the external growth stimulus is removed.
Under sustained growth stimulation, cells will progress
through the G1 phase until they reach the restriction point
located in mid to late G1. Beyond this point, cells can
complete one cell division cycle in the absence of growth
factors. This point also coincides with the last point of the
cell-cycle in which protein synthesis is required for thecompletion of one cell division. Transition from G0 in early
G1 is regulated by the cyclin D/CDK 4 or CDK6 com-
plexes. These kinases will phosphorylate p130, a member of
the Rb protein family, allowing the release and activation of
E2F4. E2F4 regulates the transcription of genes coding for
proteins necessary for the increased metabolism required for
the exit from G0 and for proteins such as E2F1 that will
regulate the transition through the G1 late phase. Sustained
growth factor stimulation and increased metabolism will
lead cells to the restriction point. Transition through this
point would mainly be regulated by the cyclin E/CDK2
complex that phosphorylates Rb, releasing the E2F1 tran-
scription factor [53]. Progression through the G1 phase is
also controlled by cyclin/CDK inhibitors such as p16ink4
(p16) for cyclin D/CDK4–6 and p27 for cyclin E/CDK2
that bind and inactivate cyclin/CDK complexes (Fig. 5A). In
asynchronously growing cells, when growth conditions are
favorable, cyclin D is up-regulated via a Ras-dependent
pathway during the G2 phase of the cell-cycle. This early
preparation might allow for a shorter G1 phase (Fig. 5B)
[54].
One of the first modifications, which has been asso-
ciated with the delayed G1 exit observed following
stimulation by growth factors or mitogens of quiescent
Bcl-2 overexpressing cells, is the increased level of p27
or its delayed degradation compared to wild-type cells
(Fig. 5A) [15,26,55,56]. Interestingly, if a mutant form of
Bcl2 where tyrosine 28 is substituted by alanine is
overexpressed, cell-cycle re-entry is not delayed and the
p27 degradation pattern is similar to that observed in
wild-type cells. In contrast, cells derived from homozy-
gous bcl-2 knockout mice [15] or from bax transgenic
mice show an accelerated G1–S transition that correlates
with lower levels of p27 and faster degradation kinetics
[15,26]. The level or the degradation kinetics of p21,
another CDK-inhibitor acting on the G1–S transition, is
not modified in quiescent Bcl-2 overexpressing cells
[15,55].
Similarly, it has also been shown that in asynchronously
growing cells, growth factor starvation or induction of
differentiation induces a faster arrest in G1 of Bcl-2 over-
  
Fig. 5. Modification of the expression pattern of cell-cycle regulators is associated with bcl-2 overexpression in quiescent cells or asynchronously growing
cells. (A) In quiescent G0 arrested cells, Bcl-2 overexpression leads to the up-regulation of p130 and p27. p130 binds E2F4 and inhibits the E2F4-dependent
transcription of genes involved in the up-regulation of cellular metabolism or in the regulation of G1 phase progression. In particular, E2F1 expression will be
inhibited. Bcl-2-dependent p27 up-regulation inhibits the cyclinE/CDK2 complex that drives cells through the restriction point. This is associated with the
phosphorylation of Rb that releases E2F1 and allows E2F1-dependent transcription. Bcl-2 could also counteract Erk activation by sequestering Raf kinase. Bcl-
2-dependent effects are drawn in red, the cell-cycle is depicted in blue and growth factor-dependent signals in black. (B) In asynchronously growing cells, Bcl-2
overexpression could modulate the point at which cells exiting from the G2/M phase enter the G0–G1 phase of the cell-cycle. In favorable growth conditions,
i.e. sufficient amounts of growth factors and nutrients, the duration, level and pattern of Bcl-2 phosphorylation would contribute to drive cells in mid to late G1
and the length of the G1 phase would be normal. In contrast, in unfavorable conditions, a different pattern of Bcl-2 phosphorylation could contribute to drive
cells in to early G1 leading either to arrest or to a slowed-down G1 transition. When cells are treated with drugs such as paclitaxel, which affect the mitotic
spindle, Bcl-2 phosphorylation is sustained leading to a delayed exit from G2/M or to death due in part to phosphorylation-induced Bcl-2 inactivation.
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arrest of the Bcl-2 overexpressing cells correlates with the
accumulation of the under-phosphorylated form of the Rb
family member p130 [58]. Similarly, quiescent Bcl-2 over-
expressing fibroblasts have increased levels of p130 com-
pared to wild-type cells (Fig. 5A) [55]. Deletion of p130 but
not Rb abrogates the cell-cycle re-entry delay induced by Bcl-
2 overexpression, indicating that the inhibition of G1–S
transition by Bcl-2 takes place before the restriction point
[55]. This was confirmed by experiments showing that
constitutive expression of E2F1 could overcome the cell-
cycle inhibition induced by Bcl-2 [55,56]. The delayed
degradation of p27 observed in Bcl-2 overexpressing cells
was also observed in p130 / cells that do not show a
delayed cell-cycle re-entry following growth factor re-addi-
tion despite Bcl-2 expression. These observations strongly
suggest that Bcl-2 also acts directly to increase the level of
p27 to inhibit cell-cycle progression. The hypothesis for a key
role of p27 in this inhibition process was supported by
experiments showing that Bcl-2 is unable to delay cell-cycle
re-entry in p27 null cells. These results indicate that the
inhibition of cell-cycle re-entry by Bcl-2 is dependent on
the joint increase of both p130 and p27 levels (Fig. 5A).
Although a recent report suggests that the regulation ofreactive oxygen species (ROS) levels by Bcl-2 might control
the level of p27 [36], the mechanisms by which Bcl-2
regulates the level of these two proteins are still largely
unknown.
As described above, the cell-cycle inhibitory function of
Bcl-2 can be regulated by its phosphorylation status. This is
also suggested by the observation that IL-3-induced serine
phosphorylation of the cytosolic fraction of Bcl-2 correlates
with the cell-cycle re-entry of growth factor-starved cells
[59].
There are few experimental data linking Bcl-2 phos-
phorylation during the G2 phase of the cell-cycle to the
accelerated cell-cycle exit observed following growth
factor starvation. However, based on the existing data it
could hypothesized that during the G2 phase of the cell-
cycle the level of Bcl-2 phosphorylation and the residue
targeted would be a sensor for growth conditions that
could participate in driving cells towards G0 or the
restriction point. In unfavorable conditions, such as
growth factor deprivation, cells would be driven towards
the G0/G1 early phase of the cell-cycle. Alternatively,
when drug-induced mytotic spindle damage occurs, the
cells would arrest in M or die. In favorable conditions,
growth factors would modify the pattern of Bcl-2 phos-
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restriction point/late G1 (Fig. 5B). This hypothesis could
explain why Bcl-2 does not notably affect the duration of
the cell-cycle in most exponentially growing cell lines,
while it accelerates cell-cycle exit following growth factor
starvation [28,57]. This is supported by recent data
showing that cells expressing a mutant form of Bcl-2
that mimics phosphorylation at threonine 69, serine 70
and serine 87, cycle more slowly and accumulate in G0/
G1 [36].5. Signal transduction pathways that could mediate the
cell-cycle inhibition induced by Bcl-2
Only a restricted number of pathways downstream of
mitogen receptors seem to be affected in Bcl-2-overex-
pressing compared to wild-type quiescent cells when they
are stimulated. Indeed, early signaling events such as
tyrosine phosphorylation or induction of early genes such
as the c-myc transcription factor are similar in wild-type orFig. 6. Pathways potentially involved in delayed cell-cycle entry induced by Bcl-2
cell-cycle entry by sequestering calcineurin (1), by decreasing the level of Ca2 + sto
ER (3). Decreased cytokine production would lead to decreased Akt activation resu
ATP levels. Increased GSK-3 activity would lead to phosphorylation and inactivatiBcl-2-overexpressing quiescent cells following either IL-3
stimulation [14] or TCR engagement [15]. However, in
quiescent Bcl-2 overexpressing BAF3 cells, IL-3 is unable
to induce a rapid activation of the ERK kinase [14]. The
decrease in ERK activity could play a role in the delayed
cell-cycle entry, as it was recently shown that in quiescent
cells, ERK activation is necessary to phosphorylate and
inhibit Rb and to drive cells through the restriction point
(Fig. 5A) [60]. A possible mechanism by which Bcl-2
overexpression could delay ERK activation is the targeting
to the mitochondria by interaction with Bcl-2 of Raf-1, a
kinase involved in the activation of ERK [61].
In T cells, delayed cell-cycle re-entry induced by Bcl-2
overexpression is associated with decreased IL-2 mRNA up-
regulation and protein production. Other cytokine mRNAs
such as those coding for IL-3 or GM-CSF are affected in a
similar manner. This inhibition is due to the impaired
nuclear translocation of the transcription factor NFAT.
NFAT translocation and transcriptional activity is induced
following its dephosphorylation by the Ca2 +/calmodulin-
dependent protein phosphatase calcineurin. Activation ofin T cells. Bcl-2 or Bcl-xl could counteract signaling pathways leading to
red inside the ER (2) or by decreasing the level of IP3-R at the surface of the
lting in increased GSK-3 activity, low metabolism activation and decreased
on of NFAT (4) while low ATP levels could counteract p27 degradation (5).
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of Ca2 + that results from opening of CRAC (Ca2 + release-
activated Ca2 + channels) channels secondary to the release
of Ca2 + from internal stores in response to the binding of
IP3 to its receptor IP3-R (Fig. 6). Inhibition of NFAT
activation by Bcl-2 could result from the sequestering of
calcineurin by membrane-bound Bcl-2. Indeed, a truncated
Bcl-2 form (DTM-bcl-2), which does not associate with the
membrane still binds calcineurin but does not inhibit NFAT
dephosphorylation and nuclear translocation. Interestingly,
the Bcl-2 residues involved in the interaction with calci-
neurin are located in the BH4 domain, which is also
involved in the binding of Raf and cell-cycle inhibition.
Activation of NFAT might also be affected indirectly by
Bcl-2 overexpression, as it has recently been shown that
Bcl-2 family members regulate the level of Ca2 + contained
in the endoplasmic reticulum. Indeed, the steady state Ca2 +
level in the endoplasmic reticulum of Bcl-2-overexpressing
cells is reduced leading to a lower cytosolic Ca2 + increase in
response to IP3 [62,63]. This would lead to a weaker Ca2 +
influx that could result in reduced calcineurin activation.
The decreased Ca2 + response to IP3 could also result from
the decreased levels of IP3-R mRNA and protein which has
been observed by Li et al. [64] in cell lines or primary T
cells overexpressing Bcl-x or Bcl-2. This leads to a reduced
Ca2 + influx following stimulation with anti-CD3 antibodies
that could contribute to reduced NFAT activation [64]. The
decreased IL-2 production associated with the reduced
NFAT activation could also be involved in the delayed
cell-cycle entry as it would lead to reduced AKT activation,
metabolism up-regulation and GSK-3 inactivation. Howev-
er, in T cells, the addition of exogenous IL-2 only partially
restores the G1–S transition which indicates that either the
calcineurin–NFAT pathway is not the only target of Bcl-2 or
that other genes essential for the G1–S transition depend on
NFAT for their expression [15].
The low level of metabolic activity that is associated
with Bcl-2-dependent survival in the absence of growth
factor leads to an atrophic status associated with low levels
of ATP and a decreased cell size [19,65,66,67]. This status
could take time to be reverted and hence would delay cell-
cycle re-entry induced by growth factor re-addition. This
hypothesis is supported by the observation that the longer
BAF3 cells are starved of IL-3, the longer they take to re-
enter S phase following growth factor re-addition [14].
However, although the level of metabolic activity has not
been investigated in growth factor-starved Y28A-bcl-2-
overexpressing cells, the fact that this mutant leads to
apoptosis inhibition without cell-cycle inhibition, strongly
argues for a direct and specific role of bcl-2 family
members in the control of G1–S cell-cycle progression.
Indeed, since metabolism activation is dependent on
growth factor stimulation, it is quite likely that the meta-
bolic slowdown associated with growth factor starvation
proceeds in a similar fashion in cells expressing Y28A-bcl-
2 or wild-type bcl-2.6. Conclusions
Overall, there is strong evidence that Bcl-2 and other
family members, in addition to their well-described effects
on apoptosis, are involved in the regulation of cell-cycle
progression. Bcl-2 appears to affect cell-cycle either at the
transition between G0/G1 and S phases or during G2/M
phase. Inhibition of G1/S transition by Bcl-2 overexpression
proceeds by modulating the level of proteins, such as p130 or
p27, involved in the control of G1/S transition. This effect
could be reinforced by the inhibitory action that Bcl-2 over-
expression can have on multiple signaling pathways involved
in the control of cell proliferation.
The effect of bcl-2 on the transition through G2/M appears
to be regulated by its phosphorylation, although no mecha-
nism of action has yet been described. However, the physi-
ological relevance as well as the importance and nature of the
different mechanisms that are involved in the control of the
cell-cycle by these proteins still need to be better defined.
One of the consequences of the inhibitory effect of Bcl-2
on the G0/G1 to S phase transition or in the G2/M phase of the
cell-cycle may be the low tumor proliferation rate in non-
Hodgkin’s lymphoma. Indeed, an inverse relationship has
been reported between Bcl-2 expression and the proliferative
activity of such tumors [11,12]. Moreover, a better prognosis
was observed for patients whose breast cancer tissue shows
high levels of Bcl-2 expression [68]. The inhibitory effect of
Bcl-2 on proliferation may also account for the relative low
incidence of lymphomas in mice expressing the bcl-2 trans-
gene in either T or B lymphocytes [69,70,71].Acknowledgements
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